

Table 7.6i
Immunosuppression Use for Antirejection Treatment from Transplant
to One Year Following Transplantation, 1998 to 2007
Recipients with Pancreas After Kidney (PAK) Transplants

	Year of Transplant									
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
Transplants	156	220	305	305	375	344	420	343	293	261
Tx with Antirejection Treatments	44	57	65	45	43	61	59	46	32	33
Antibodies										
Any in Category	59.1%	75.4%	53.8%	60.0%	48.8%	65.6%	59.3%	76.1%	68.8%	72.7%
Atgam/NRATG/NRATS	9.1%	1.8%	1.5%	2.2%	0.0%	3.3%	0.0%	0.0%	0.0%	0.0%
OKT3	45.5%	63.2%	35.4%	26.7%	25.6%	13.1%	15.3%	13.0%	15.6%	12.1%
Thymoglobulin	2.3%	22.8%	21.5%	33.3%	30.2%	45.9%	44.1%	63.0%	59.4%	63.6%
Zenapax	2.3%	1.8%	1.5%	2.2%	2.3%	6.6%	0.0%	4.3%	3.1%	3.0%
Simulect	0.0%	0.0%	4.6%	4.4%	0.0%	4.9%	0.0%	2.2%	3.1%	0.0%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	27.9%	8.5%	6.5%	3.1%	6.1%
Corticosteroids										
Any in Category	70.5%	84.2%	87.7%	86.7%	90.7%	68.9%	79.7%	63.0%	68.8%	84.8%
Steroids	70.5%	84.2%	87.7%	86.7%	90.7%	68.9%	79.7%	63.0%	68.8%	84.8%
Antimetabolites										
Any in Category	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Methotrexate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.